Hepatic encephalopathy Market Analysis 2034: Prevalence, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Pipeline, Epidemiology, IND, NDA Approval and Companies by DelveInsight

Hepatic Encephalopathy Companies working in the market are Vedanta Biosciences, Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Patricia Bloom, Rebiotix, and others
(Albany, USA) DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Hepatic Encephalopathy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hepatic Encephalopathy market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Hepatic Encephalopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hepatic Encephalopathy market.

To Know in detail about the Hepatic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatic Encephalopathy Market Forecast [https://www.delveinsight.com/report-store/hepatic-encephalopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Hepatic Encephalopathy Market Report:

* The Hepatic Encephalopathy market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
* The total Hepatic Encephalopathy Market Size in the 7MM was ~USD 1,680 Million in 2023 and is projected to increase during the forecast period (2024-2034).
* Key Hepatic Encephalopathy Companies: Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix, and others
* Key Hepatic Encephalopathy Therapies: Xifaxan (Rifaximin/OHE7), AXA1665, GR3027 (Golexanolone), and others.
* The Hepatic Encephalopathy market size in seven major markets was USD 1,563 million in 2021, which is further expected to increase by 2034 at a Compound Annual Growth Rate (CAGR) of 4.66% for the study period (2020-2034)
* The total diagnosed prevalent cases of Cirrhosis (hospitalized) in the 7MM was found to be 862,508 cases in 2021. These cases are expected to increase by 2034 at a CAGR of 0.63% during the study period (2020-2034).
* The Hepatic Encephalopathy diagnosed prevalent cases in the 7MM are expected to increase at a CAGR of 0.61% for the study period of 2020-2034.
* Among 7MM, the United States has the highest diagnosed prevalent cases of hepatic encephalopathy with 205,664 cases in 2021.
* Assessments as per DelveInsight's analysts show that the majority of cases of Hepatic Encephalopathy are occupied by males as compared to females. There was a total of 149,518 male and 56,146 female cases of Hepatic Encephalopathy in 2021 in the United States.
* The agespecific data revealed that the highest number of Hepatic Encephalopathy people affected with was found in the age group of 45-54 years, while people
* The Hepatic Encephalopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatic Encephalopathy pipeline products will significantly revolutionize the Hepatic Encephalopathy market dynamics.
* On November 18, 2024, Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the first look at its late-stage RED-C clinical trial program which will be presented at the American Association for the Study of Liver Disease (AASLD), The Liver Meeting Registered in San Diego, CA. This clinical program was designed to assess the efficacy of a next generation therapeutic, a soluble solid dispersion (SSD) immediate-release rifaximin product, to delay onset of first overt hepatic encephalopathy (OHE) hospitalization. There are no medications globally approved for the primary prophylaxis and delay in decompensation to first episode of OHE in cirrhosis. Another objective of this study is to assess the effects of treatment with this next generation therapeutic on the time to the onset of significant clinical events, including all-cause hospitalization rates, first occurrence of OHE event requiring hospitalization, and all-cause mortality.
* As of September 27, 2024, Neuropathix is developing therapies for hepatic encephalopathy, with drugs in various stages of development.
* ASKA Pharmaceutical and University of Tsukuba: Both companies are involved in the development of hepatic encephalopathy treatments, with updates reported as of September 27, 2024.

Hepatic Encephalopathy Overview

Hepatic encephalopathy (HE) is a brain disorder that occurs in some individuals with liver disease. HE manifests as a spectrum of neuropsychiatric symptoms, ranging from subtle cognitive impairments to coma, significantly contributing to morbidity in liver disease patients. It is seen in acute liver failure, liver bypass procedures such as shunt surgery and transjugular intrahepatic portosystemic shunt (TIPS), and cirrhosis, classified respectively as Type A, B, and C HE.

Hepatic encephalopathy can present with more severe symptoms, including reduced alertness, shortened attention span, sleep pattern disruptions, mild confusion, slowed mental task performance, and mood or personality changes. More pronounced changes in memory, concentration, or intellectual function than those observed in minimal hepatic encephalopathy (MHE) may also occur.

The pathophysiology of Hepatic encephalopathy is multifactorial, involving agents such as ammonia (NH3), inflammatory cytokines, manganese deposition in the basal ganglia, and benzodiazepine-like compounds (e.g., gamma-aminobutyric acid [GABA]). Recent studies have also highlighted the roles of microbiota and aromatic amino acids. While the pathogenesis of Hepatic encephalopathy is complex and not fully understood, with multiple factors leading to functional impairment of neuronal cells, ammonia is considered the primary pathophysiologic mechanism.

Hepatic encephalopathy is classified into two broad categories based on severity: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE). When individuals exhibit obvious, outward signs and symptoms, the condition is referred to as OHE.

Hepatic Encephalopathy Epidemiology

The Hepatic encephalopathy epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Hepatic Encephalopathy epidemiology trends @ Hepatic Encephalopathy Epidemiology Forecast [https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Hepatic Encephalopathy Epidemiology Segmentation:

The Hepatic Encephalopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Hepatic Encephalopathy
* Prevalent Cases of Hepatic Encephalopathy by severity
* Gender-specific Prevalence of Hepatic Encephalopathy
* Diagnosed Cases of Episodic and Chronic Hepatic Encephalopathy

Hepatic Encephalopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatic Encephalopathy market or expected to get launched during the study period. The analysis covers Hepatic Encephalopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hepatic Encephalopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatic Encephalopathy Key Companies

Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix, and others.

Hepatic Encephalopathy Therapies

Xifaxan (Rifaximin/OHE7), AXA1665, GR3027 (Golexanolone), and others

Discover more about therapies set to grab major Hepatic Encephalopathy market share @ Hepatic Encephalopathy Treatment Landscape [https://www.delveinsight.com/report-store/hepatic-encephalopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Hepatic Encephalopathy Market Outlook

The United States holds a significant share of the Hepatic Encephalopathy (HE) market compared to other regions, including the EU5 (Italy, Spain, United Kingdom, France, and Germany) and Japan.

Management of overt hepatic encephalopathy (OHE) focuses on treating acute episodes, preventing recurrence, and identifying and managing precipitating factors. The two primary medical therapies for HE are non-absorbable disaccharides (such as lactitol and lactulose) and non-absorbable antibiotics (such as rifaximin). The hyperammonemia and inflammation caused by urea breakdown in cirrhotic patients have led to the development of treatments targeting gut bacteria. Treatments for OHE are approved by the US FDA, although some unapproved treatments are also used. It is crucial to consider that in patients with cirrhosis and portosystemic shunting, skeletal muscle mass and renal clearance play essential roles in clearing neurotoxins.

Treatment options for Hepatic encephalopathy are based on prior experience with patients who have episodic HE. Due to the lack of clinical signs, covert hepatic encephalopathy (CHE) is rarely recognized or treated outside of clinical trials. Treatment for CHE is on an as-needed basis, with a 4- to 8-week trial of lactulose as the first-line treatment. If the patient shows improvement, the treatment can continue. However, due to the high cost, rifaximin is typically not used for CHE.

According to DelveInsight, the Hepatic Encephalopathy market size in the 7MM (seven major markets) is expected to change significantly during the study period from 2020 to 2034.

Download the report to understand which factors are driving Hepatic Encephalopathy market trends @ Hepatic Encephalopathy Market Dynamics [https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Hepatic Encephalopathy Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Hepatic Encephalopathy Companies: Dana-Farber Cancer Institute, Huabo Biopharm Co., Ltd., Beijing Scitech-Mq Pharmaceuticals, Oxford BioMedica, Hutchison Medipharma Limited, Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Pfizer, Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, SCRI Development Innovations, LLC, Astellas Pharma Inc, and others
* Key Hepatic Encephalopathy Therapies: Xifaxan (Rifaximin/OHE7), AXA1665, GR3027 (Golexanolone), and others
* Hepatic Encephalopathy Therapeutic Assessment: Hepatic Encephalopathy current marketed and Hepatic Encephalopathy emerging therapies
* Hepatic Encephalopathy Market Dynamics: Hepatic Encephalopathy market drivers and Hepatic Encephalopathy market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Hepatic Encephalopathy Unmet Needs, KOL's views, Analyst's views, Hepatic Encephalopathy Market Access and Reimbursement

Learn more about the emerging Hepatic Encephalopathy therapies & key companies @ Hepatic Encephalopathy Clinical Trials [https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Hepatic Encephalopathy Market Report Introduction

2. Executive Summary for Hepatic Encephalopathy

3. SWOT analysis of Hepatic Encephalopathy

4. Hepatic Encephalopathy Patient Share (%) Overview at a Glance

5. Hepatic Encephalopathy Market Overview at a Glance

6. Hepatic Encephalopathy Disease Background and Overview

7. Hepatic Encephalopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Hepatic Encephalopathy

9. Hepatic Encephalopathy Current Treatment and Medical Practices

10. Hepatic Encephalopathy Unmet Needs

11. Hepatic Encephalopathy Emerging Therapies

12. Hepatic Encephalopathy Market Outlook

13. Country-Wise Hepatic Encephalopathy Market Analysis (2020-2034)

14. Hepatic Encephalopathy Market Access and Reimbursement of Therapies

15. Hepatic Encephalopathy Market Drivers

16. Hepatic Encephalopathy Market Barriers

17. Hepatic Encephalopathy Appendix

18. Hepatic Encephalopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatic-encephalopathy-market-analysis-2034-prevalence-ema-pdma-fda-approvals-clinical-trials-medication-pipeline-epidemiology-ind-nda-approval-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.